Cantargia
1,715
SEK
-7,25 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1.312 investorer følger denne virksomhed
-7,25%
-5,35%
-50,97%
-61,96%
-54,12%
-55,78%
-89,04%
-89,61%
-75,73%
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Læs mereMarkedsværdi
472,53 mio. SEK
Aktieomsætning
2,48 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
21.2
2025
Årsrapport '24
13.5
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '24
ViserAlle indholdstyper
Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer
Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools